CD360抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of K562 cells using CD360 mouse mAb (green) and negative control (red).    

  
  

CD360 antibody targets CD360. a cell surface molecule belonging to the T-cell immunoglobulin and mucin (TIM) family, primarily expressed on immune cells like T cells, natural killer (NK) cells, and antigen-presenting cells. Initially identified for its role in immune regulation, CD360 (also known as TIM-family member) is implicated in modulating immune activation and tolerance. Structurally, it contains an immunoglobulin variable domain and a mucin-like region, enabling interactions with ligands such as phosphatidylserine, which is exposed on apoptotic cells. This interaction suggests a role in phagocytosis and clearance of cellular debris, linking CD360 to homeostasis and immune response modulation.

Research highlights CD360's dual role in immunity: it can promote pro-inflammatory responses in certain contexts while suppressing immune activity in others, depending on ligand engagement and cellular environment. Dysregulation of CD360 signaling is associated with autoimmune diseases, chronic infections, and cancer, where its overexpression or inhibition correlates with disease progression. Therapeutic antibodies targeting CD360 aim to either block or enhance its signaling to restore immune balance. Preclinical studies explore its potential in treating malignancies and autoimmune disorders, positioning CD360 as a promising immunotherapeutic target. Further research is needed to fully elucidate its mechanistic pathways and clinical applications.